A Child 'Punished for Not Being Profitable...' -- A Mother's Comment

Comments on CIRM's stance on gene therapy and commercialization

Some readers have remarked on Monday’s item dealing with the California stem cell agency’s stance on issues involved in a company’s  abandonment of a clinical  trial for a succesful treatment of the bubble baby disease. 

One comment came from a mother of a child with the affliction, medically known as ADA-SCID. She said, “We have fought hard to keep Jako…